Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers by Glodzik, D. et al.
                                                              
University of Dundee
Mutational mechanisms of amplifications revealed by analysis of clustered
rearrangements in breast cancers
Glodzik, D.; Purdie, C.; Rye, I. Hansine; Simpson, P.; Staaf, J.; Span, P. N.; Russnes, H.; Nik-
Zainal, S.
Published in:
Annals of Oncology
DOI:
10.1093/annonc/mdy404
Publication date:
2018
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Glodzik, D., Purdie, C., Rye, I. H., Simpson, P., Staaf, J., Span, P. N., ... Nik-Zainal, S. (2018). Mutational
mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers. Annals of
Oncology, 29(11), 2223-2231. https://doi.org/10.1093/annonc/mdy404
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
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Background: Complex clusters of rearrangements are a challenge in interpretation of cancer genomes. Some clusters of
rearrangements demarcate clear amplifications of driver oncogenes but others are less well understood. A detailed analysis of
rearrangements within these complex clusters could reveal new insights into selection and underlying mutational mechanisms.
Patients and methods: Here, we systematically investigate rearrangements that are densely clustered in individual tumours in
a cohort of 560 breast cancers. Applying an agnostic approach, we identify 21 hotspots where clustered rearrangements recur
across cancers.
Results: Some hotspots coincide with known oncogene loci including CCND1, ERBB2, ZNF217, chr8:ZNF703/FGFR1, IGF1R, andMYC.
Others contain cancer genes not typically associated with breast cancer:MCL1, PTP4A1, andMYB. Intriguingly, we identify clustered
rearrangements that physically connect distant hotspots. In particular, we observe simultaneous amplification of chr8:ZNF703/
FGFR1 and chr11:CCND1where deep analysis reveals that a chr8–chr11 translocation is likely to be an early, critical, initiating event.
Conclusions: We present an overview of complex rearrangements in breast cancer, highlighting a potential new way for
detecting drivers and revealing novel mechanistic insights into the formation of two common amplicons.
Key words: breast cancer, genome, rearrangements, mutational mechanism, selection, ampliﬁcation
Background
Extensive copy number characterisation using comparative gen-
omic hybridisation (CGH) technology has led to remarkable
insights into the somatic genetics of breast cancer, including
identification of recurrent whole arm gains and losses, homozy-
gous deletions (e.g. CDKN2A/B, PTEN) and large, common, re-
current driver amplifications (e.g. ERRB2, CCND1) [1–4].
Despite the increasing resolution provided by CGH technology,
there remains a limit to the resolution of detection of copy num-
ber aberrations (CNAs) of several hundred kilobases (kb) (sup-
plementary Figure S1, available at Annals of Oncology online) [5].
However, CNAs are demarcated by rearrangements that can be
detected from whole-genome sequences even when the size of the
abnormal copy number segment is as small as 1 kb.
Somatic rearrangements are extremely diverse. Inter-patient vari-
ation exists in the quantity, type and distribution of somatic rear-
rangements even in cancers of the same tissue type [6, 7] and the
consequences of rearrangements can also vary considerably. Solitary
or low numbers of rearrangement breakpoints may directly confer
selective advantage; for example breakpoints that transect tumour
suppressor genes or that generate in-frame gene fusion events, such
as ETV6-NTRK3 in breast cancer and TMPRSS-ERG fusions in
prostate cancer [8, 9]. Collections of breakpoints can reflect driver
amplifications. They can also be markers of complex, stochastic
chromosomal events (e.g. chromoplexy, chromothripsis) [7, 10, 11]
and provide increased resolution in studying mechanisms under-
pinning CNAs, for example, revealing that breakage-fusion bridge
sometimes underpins the formation of the ERBB2 amplicon [12].
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Methods
Recently, 560 whole-genome sequenced breast cancers were expansively
curated for somatic mutations, including rearrangements [5]. We previ-
ously defined ‘clustered’ rearrangements as clusters of breakpoints that
occurred at high density in individual cancer genomes (see supplementary
Methods, available at Annals of Oncology online). In the current study, we
focus on characteristics of clustered rearrangements in 560 breast cancers
that so far remained unexplored. In order to assess the impact of clustered
rearrangements on breast cancer, we identified chromosomal hotspots
where clustered rearrangements recurred in samples from different
patients. Using the Piecewise-Constant-Fitting (PCF) algorithm [13] (see
supplementary Methods, available atAnnals of Oncology online), we sought
genomic segments where groups of rearrangements exhibited short inter-
mutation distances, indicative of ‘hotspots’ that are more frequently rear-
ranged than the background rate. Using this method, we identified highly
rearranged genomic loci that recurred in breast cancers. These sites make
important contributions to tumorigenesis and reveal mechanisms under-
pinning chromosomal instability.
Results
PCF-based method identifies 21 hotspots of
clustered rearrangements across 560 breast
cancers
There were 624 clusters of rearrangements in individual breast
cancer genomes, comprising 17 247 intra-chromosomal rear-
rangements, and 6509 inter-chromosomal translocations.
Clusters of rearrangements were common: 372 of 560 samples
had at least one and were almost as frequent in triple-negative
breast cancers (0.96 rearrangement clusters per sample) as in
oestrogen receptor (ER)-positive breast cancers (1.00 rearrange-
ment clusters per sample). Among PAM50 subtypes, luminal A
cancers had fewest rearrangement clusters per sample (0.6, 95%
Poisson CI 0.5–0.9) compared with other subtypes (luminal B
1.2, CI 1.0–1.5 and basal 1.2, CI 1.0–1.5).
To identify loci where clusters of rearrangements recur across
multiple independent tumour samples, we pooled all breakpoints
in the ‘clustered’ category and sorted them according to position
in the reference genome. PCF was applied to find hotspot regions
in the genome that are recurrently affected by clusters of break-
points in multiple patients (Figure 1A and B for workflow).
In all, 21 such hotspots of clustered rearrangements were identified
(Figure 1C, supplementary Table S1 and Figures S2 and S3, available
at Annals of Oncology online), encompassing 8% of the genome, but
involving 46% of all breakpoints of clustered rearrangements.
Recurrent clustered rearrangements identify
common, large driver amplicons as well as rare,
smaller amplicons
Breakpoint densities for each of the 21 hotspots of clustered rear-
rangements identified in chromosomes 1, 6, 8, 11, 12, 15, 17, 19,
20 and 21 ranged between 35 and 165 breakpoints per Mb. We
expected to find common driver amplification regions such as
CCND1, ERBB2, ZNF217, chr8:ZNF703/FGFR1, IGF1R, and
MYC as sites of clustered rearrangements recurring across many
patients (Figure 1C). These were identified without exception.
Hotspots were also identified at GNAS, RUNX1, and MDM2, all
recognised as breast cancer genes, even if less frequent.
Interestingly, several hotspots of clustered rearrangements were
found near oncogenes that are not typically associated with breast
cancer. Curation revealed that a subset had focal copy number
gains typical of driver amplicons, albeit on a smaller scale (supple-
mentary Figure S4, available at Annals of Oncology online). These
hotspots at or near MCL1 (5.7% samples, 2.7% resulting in MCL1
amplification), PTP4A1 (4.5% samples, 1.25% PTP4A1 amplifica-
tion) and MYB (6.3%, 1.4% MYB amplification) occurred at lower
frequencies than that of common breast cancer amplicons (supple-
mentary Figures S5 and S6 and Note 1, available at Annals of
Oncology online for gene expression analysis). Further experiments
will be required to verify whether these rarer, smaller and more
modest amplicons are indeed driver events.
Co-occurring hotspots: Inferring co-evolution
through detailed breakpoint analyses
Apart from an increased resolution in identifying copy number
changes, whole-genome sequencing provides information to
base-pair level about direct, physical connections between dispar-
ate genomic locations. Each of the 21 hotspots was identified in-
dependently through an agnostic approach. If we find that
different hotspots are co-occurring at a higher frequency than
would be expected, and further are physically connected to each
other, this would suggest co-evolution of those allegedly
independent hotspots, regardless of their original location on
chromosomes. Below we report on two observations—an intra-
chromosomal and an inter-chromosomal example—that provide
insights into putative drivers and mutational mechanisms.
Co-evolving clusters on chromosome 6: possible
driver loci?
Four distinct hotspots of clustered rearrangements were identified
on chromosome 6; the small amplicon attributed to PTP4A1
(chr6: 63.3Mb) and three larger hotspots at chr6: 96.6Mb, chr6:
117.6Mb and chr6: 128.5Mb (Figure 2A, supplementary Figure S6,
available at Annals of Oncology online). Although they are inde-
pendently identified loci, first we found that the four hotspots
occurred together in different combinations in 10 samples (1.7%
of cohort, Figure 2C). Second, they were also frequently physically
linked through intra-chromosomal rearrangements indicating that
they arose or evolved together during tumorigenesis (Figure 2B).
If recurrence of rearrangement clusters is an indicator of putative
driver events, then co-occurrence of such hotspots would further
contribute to the possibility that they are under selective pressure.
Co-evolving chr8:ZNF703/FGFR1 and CCND1
amplicons reveal two chromosome fusions
underpinning amplicon formation
The chr8:ZNF703/FGFR1 and chr11:CCND1 amplifications are
amongst the most frequent in breast cancer, particularly in ER-
positive breast tumours (19% and 28%, respectively, of amplifi-
cations in ER-positive tumours; 11% and 16%, respectively, of
total cohort). These amplifications have been described before to
occur more frequently together in breast cancers, than expected
[14]. However, the mechanism underlying these co-occurring
amplifications remains uncertain with diverse structural out-
comes reported previously [15].
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Here, in agreement with previous reports [14], we find co-
occurrence of the amplifications of chr8:ZNF703/FGFR1 and
chr11:CCND1 in 26 patients (5% of total cohort), a frequency
higher than expected than if they were independent events
(Fisher’s exact test, P¼ 1.9e5, supplementary Table S2, available
at Annals of Oncology online).
Furthermore, we detect translocation breakpoints connecting
the chr8:ZNF703/FGFR1 and chr11:CCND1 amplicons in 11 out
of 26 patients with co-occurring amplifications (42%; Figure 3
for a detailed analysis of a single sample), showing that these
amplicons are often physically connected. This phenomenon of
co-localising chr8:ZNF703/FGFR1 and chr11:CCND1 amplicons
tends to be seen in ER-positive tumours, among patients diag-
nosed at an older age (Figure 4).
To confirm physical proximity of the chr8:ZNF703/FGFR1 and
chr11:CCND1 amplicons, FISH analysis was carried out on four
samples. Nuclear co-localisation of the chr8:ZNF703/FGFR1 and
chr11:CCND1 amplicons was observed. In three samples, the
counts of co-amplified signals were sufficient to confidently es-
tablish co-localisation of the amplicons in nuclei (Figure 3D, sup-
plementary Figure S7, available at Annals of Oncology online).
The co-localisation of the amplified sequences confirms linked
co-evolution of amplicons that were originally located on separ-
ate chromosomes.
In 10 samples, the translocations only connect chromosomes 8
and 11 (Figure 5), while in the remaining sample PD13608a, five
other chromosomes were also involved (supplementary Figure
S8, available at Annals of Oncology online). In 7 out of the 10 sam-
ples where only chromosomes 8 and 11 are involved, there is a
translocation which joins the lower-most coordinate of the
chr8:ZNF703/FGFR1 amplicon, located on 8p, to the higher-most
coordinate of the chr11:CCND1 amplicon, located on 11q
(marked with asterisks in Figure 5). The translocations are associ-
ated with chromosomal copy number loss terminal to the break-
points (seen as 8p and 11q loss-of-heterozygosity respectively
marked in pale red in Figure 5). This observation implies that a
chr8–chr11 translocation with associated loss of portions of the
chromosome terminal to the breakpoint is likely to be an early,
critical, initiating event in the tumours where they were found.
Moreover, in the 10 samples, there are many additional chr8/
chr11 translocations in each patient, and these additional translo-
cations are distant from the predicted driver amplifications
(ZNF703/FGFR1 and CCND1, respectively). Additionally, some
intervening sequences were lost. The translocations demarcate
borders of chromosomal segments where the difference in total
copy number is particularly marked: Figure 3C depicts ‘copy
number steps’ at rearrangement breakpoints which are calculated
as the absolute difference in total copy number between 5-kb
Figure 1. Identiﬁcation of hotspots of clustered rearrangements in breast cancers. (A) Workﬂow. (B) Schematic of clusters of rearrangements
in individual samples, some of which form hotspots (grey shading). (C) Chromosomal localisation of breakpoints of rearrangements across
560 breast cancer genomes shown as counts (1Mb bins). Chromosomes are depicted around the outside of the circle. Twenty-one hotspots
of clustered rearrangements are shown in red. Positions of genes within each hotspot are indicated. Supplementary Figure S2, available at
Annals of Oncology online shows a weighted histogram which is robust with respect to extremely rearranged individual samples.
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Figure 2. Clustered rearrangements on chromosome 6. (A) Four hotspots identiﬁed on chromosome 6 are indicated by the black lines and
grey shading. (B) Examples of samples with clustered rearrangements affecting multiple hotspots on chromosome 6: PD13425a, PD4847a,
PD6422a. Copy number (y-axis) depicted as black dots (10-kb bins, see online methods for details of copy number estimation). Lines repre-
sent rearrangements breakpoints (green ¼ tandem duplications, red ¼ deletions, blue ¼ inversions, pink ¼ inter-chromosomal transloca-
tions). Pink numbers above breakpoints indicate chromosome where second breakpoint of translocations were found. (C) Matrix indicating
samples with clustered rearrangements (in black) focusing on the four hotspots, with samples rearranged in multiple hotspots to the right—
samples shown in detail in (B) are highlighted with asterisks.
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Figure 3. Analysis of FGFR1 and CCND1 co-ampliﬁcation in sample PD4965a. (A) Circos plot showing rearrangements, loss of heterozygosity
(LOH) (red) and copy number gain (green). Chromosomal ideogram depicted on outermost circle. Lines in the centre of the circle show rear-
rangements (colours described in Figure 2). (B) Representation of two chromosomes connected by translocations. Copy number (y-axis) and
lines represent rearrangements breakpoints described as in Figure 2. (C) Copy number changes at rearrangement breakpoints (dot ¼ rear-
rangements breakpoint, colours as described in Figure 2), with biggest differences at translocation breakpoints. (D) FISH analysis of the same
tumour (bottom): frozen sections of tumour were probed for CCND1 (red) and FGFR1 (green) and the respective chromosome centromeres.
Subset (i) shows a normal cell nucleus with a single copy of both genes. Subset (ii) shows a tumour cell nucleus with multiple FGFR1 (green)
signals (average 14.9/nucleus when counting 60 nuclei) and two chromosome 8 centromere (red) signals. Subset (iii) shows two tumour cell
nuclei with multiple CCND1 (red) signals (average 10.4/nucleus when counting 60 nuclei) and two chromosome 11 centromere (green) sig-
nals. Main FISH image shows combination of CCND1 (red) and FGFR1 (green) probes across multiple tumour cell nuclei. Note signiﬁcant co-
ampliﬁcation of both genes and clustering of signals indicating co-evolving of the ampliﬁcation/translocation in this case.
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regions to the left and to the right of a breakpoint in the reference
genome. In 7 out of the 10 samples, we found that the largest
copy number steps were observed at breakpoints of these add-
itional chr8/chr11 inter-chromosomal translocations as com-
pared with intra-chromosomal rearrangements (supplementary
Table S3, available at Annals of Oncology online). In all 10 sam-
ples, there are examples of inter-chromosomal breakpoints with
copy number steps of 3 or more. Amplifications of translocation
breakpoints are therefore frequent.
To confirm this analytical observation, FISH analysis was car-
ried out on ancillary translocation breakpoints that are distant
from the target driver gene in sample PD18733a. The FISH ana-
lysis confirmed high amplification of translocation breakpoints
and their co-localisation in the nuclei (supplementary Methods
and Figure S9, available at Annals of Oncology online). In terms of
the chronology of events, the amplification of these loci must
have occurred after the formation of the multiple translocations
between the pairs of same two chromosomes.
We propose the following model: the formation of the
chr8:ZNF703/FGFR1 and chr11:CCND1 amplicons is initiated by
a translocation between 8p and 11q resulting in copy number
losses terminal to the translocation breakpoints (Figure 6). A di-
centric chromosome is formed that likely shatters during cell div-
ision, creating multiple opportunities for further translocation
rearrangements to form between pieces of chr8 and chr11. Some
intervening genomic pieces may be lost, while some retained and
then amplified, producing the patterns of high-level
amplification delimited by translocations that we observe to be
interspersed by copy number loss/neutral regions in these breast
cancers.
Chromosome arm loss and amplicon formation
According to the model, losses of chromosome arms 8p and 11q
precede formation of the amplicons. To further evaluate this hy-
pothesis, we assessed the frequency of 8p and 11q losses across
the cohort. Eleven out of thirteen samples with independent
amplifications of both, but without rearrangements between the
two chromosomes also display loss of 8p and 11q (supplementary
Figures S10 and S11, available at Annals of Oncology online). Arm
losses are often associated with amplifications: out of 274 samples
with 8p loss, 168 (61.3%) displayed amplicons elsewhere on the
chromosome. Out of 237 samples with 11q loss, 97 (40.9%) dis-
played chr11:CCND1 gain. The majority of amplifications are
accompanied by adjacent chromosome arm losses, but not all
chromosomes with arms losses developed amplifications.
Is the mutational process unique to
co-amplifications of chr8:ZNF703/FGFR1
and chr11:CCND1?
The mechanistic steps underpinning the co-amplifications be-
tween chromosomes 8 and 11 could be specific to the two sites or
may be a more generalised phenomenon.
Figure 4. Comparison of clinical data for groups of patients with chr8:ZNF703/FGFR1 and chr11:CCND1 ampliﬁcations. (A) Venn diagram for
groups of patients deﬁned by ampliﬁcations and chr8/11 translocations. (B) Age, breast cancer subtype and PAM50 classiﬁcation of the pa-
tient groups. (C) Relapse-free survival for the patient groups. Different age distributions and therapies between groups confound this
comparison.
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Figure 5. Representation of ten samples with FGFR1/CCND1 ampliﬁcations and translocations between the two amplicons. Copy number (y-
axis) and lines represent rearrangements as described in Figure 2. Translocations joining the lowest coordinates of chr8:ZNF703/FGFR1 ampli-
con to the highest coordinate of chr11:CCND1 amplicon highlighted with asterisks. Segments of LOH are marked in pale red colour.
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To explore this, we searched for other examples of co-occurring
driver amplifications and assessed the patterns of rearrangements
demarcating them. Co-amplifications of other driver loci in breast
cancer are observed, for example chr20:ZNF217 and chr8:MYC is
seen in 18 samples (P¼ 1e04) and chr20:ZNF217 and
chr8:ZNF703 in 11 samples (P¼ 9e03) (supplementary Table S1,
available at Annals of Oncology online). However, these co-
amplifications did not show enrichment of translocations between
affected chromosomes, nor did they exhibit simultaneous telomer-
ic loss beyond the translocation breakpoint. Thus, although other
co-occurring amplifications exist, they do not arise via the same
mechanism of fusion of two chromosomes that results in the
chr8:ZNF703/FGFR1 and chr11:CCND1 co-amplifications.
Finally, we conducted an exhaustive search for clustered rear-
rangements with similar genomic properties to the chr8–chr11 co-
amplifications. We identified six other samples with clustered rear-
rangements involving two chromosomes that had translocations
connecting the two chromosomes, and had adjacent losses of
chromosome arms (supplementary Figure S12 and S13, available at
Annals of Oncology online). Although chromosome 8 or 11 was
involved in five of the six identified events, no other chromosomal
pair was recurrent unlike in the chr8–chr11 co-amplifications.
Discussion
Alternative way of detecting drivers—recurrence
and co-occurrence
Traditionally, recurrence of exonic mutations has been used as evi-
dence for selection, particularly for single-base substitutions and
frameshifting insertions/deletions. The principle of recurrence has
also been used to detect selection for simple somatic rearrange-
ments [16]. Here, we describe recurrent clustered rearrangements
of a more complex nature; some of which span multiple regions on
single or multiple chromosomes. Detailed analyses of the rearrange-
ments forming these complex events suggest a role of selection in
their formation. We observed co-evolution of clustered rearrange-
ments recurrently affecting disparate hotspot regions on a single
chromosome (e.g. chromosome 6), as well as on different chromo-
somes (e.g. co-amplifications of chromosomes 8 and 11). We posit
that such chromosomal events are unlikely to occur by chance.
Rare amplicons detected by analysis of clustered
rearrangements
In addition to known driver amplicons, we identified novel
regions of the genome that are recurrently affected by clustered
rearrangements, albeit at moderate frequency. Some of these
events increase the number of copies of oncogenes, but further
functional work is required to demonstrate whether they are
driver events in breast cancer.
Deep analysis of co-occurrence reveals novel muta-
tional mechanisms
The processes that lead to co-occurring amplifications of the
chr8:ZNF703/FGFR1 and chr11:CCND1 loci are particularly intri-
guing, as we identified recurrent translocations between the two
regions suggesting co-evolution. Indeed, the fusion of two chromo-
somes appears to be the initiating mechanistic event in a substantial
proportion of these tumours. The co-evolution of the
chr8:ZNF703/FGFR1 and chr11:CCND1 amplicons has been subject
CCND1
1. initiating translocation
ZNF703 chr8
2. formation of dicentric chromosome with loss of terminal of 8p &11q
3. dicentric chromosome shatters during mitosis to generate fragments of chr8 & chr11
4. loss of some DNA fragments and suturing of others to form more 8;11 translocations
5. reassembly and amplification
potential for circular 
chromosomes (s)
potential for breakage-fusion-bridge
Figure 6. Proposed mechanism for FGFR1/CCND1 co-ampliﬁcations.
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of controversy in the literature [14, 15]. Among tumours with co-
amplifications in our cohort, there are examples of independent
evolution and of linked co-evolution. The novel mutational process
that is described here directly contributes towards the high fre-
quency of the co-amplifications observed in breast cancers.
Conclusions
Clustered rearrangements are common in breast cancer genomes,
and often associated with gene amplifications that drive oncogen-
esis. Understanding the process of amplicon formation, an ex-
ample of which we present here for the chr8:ZNF703/FGFR1 and
chr11:CCND1 co-amplifications, will be important for our
understanding of the origins of a subset of breast cancers.
Acknowledgements
We would like to thank Tauanne Dias Amarante and Helen
Davies for their help with editing the article, and Yilong Li for
his visualisations of rearranged chromosomes.
Funding
Data used in this analysis were previously published and was
funded through: Breast Cancer Somatic Genetics Study
(BASIS), European Community’s Seventh Framework
Programme (FP7/2010-2014; 242006; Triple Negative project
(Wellcome Trust 077012/Z/05/Z) and HER2þ project (Institut
National du Cancer France (grant Nos 226-2009, 02-2011, 41-
2012, 144-2008, 06-2012)), Korean Health Technology R&D
Project, Ministry of Health & Welfare, (A111218-SC01),
Wellcome Trust Strategic Award (101126/B/13/Z). DG was sup-
ported by the EU-FP7-SUPPRESSTEM project and subsequent-
ly by Lund University. SN-Z is funded by CRUK Advanced
Clinician Scientist Award (C60100/A23916). IHR and HGR are
grateful for funding from Health Region South-East, Norway
and from The Norwegian Cancer Society.
Disclosure
DG and SN-Z are inventors on several patent applications. All
remaining authors have declared no conflicts of interest.
References
1. Ching HC, Naidu R, Seong MK, Har YC et al. Integrated analysis of copy
number and loss of heterozygosity in primary breast carcinomas using
high-density SNP array. Int J Oncol 2011; 39(3): 621–633.
2. Fang M, Toher J, Morgan M et al. Genomic differences between estrogen
receptor (ER)-positive and ER-negative human breast carcinoma identi-
fied by single nucleotide polymorphism array comparative genome hy-
bridization analysis. Cancer 2011; 117(10): 2024–2034.
3. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-
related gene in a human mammary carcinoma. Science 1985; 229(4717):
974–976.
4. Cairns P, Polascik TJ, Eby Y et al. Frequency of homozygous deletion at
p16/CDKN2 in primary human tumours. Nat Genet 1995; 11(2):
210–212.
5. Nik-Zainal S, Davies H, Staaf J et al. Landscape of somatic mutations in
560 breast cancer whole-genome sequences. Nature 2016; 534(7605):
47–54.
6. Drier Y, Lawrence MS, Carter SL et al. Somatic rearrangements across
cancer reveal classes of samples with distinct patterns of DNA breakage
and rearrangement-induced hypermutability. Genome Res 2013; 23(2):
228–235.
7. Willis NA, Rass E, Scully R. Deciphering the Code of the Cancer
Genome: mechanisms of Chromosome Rearrangement. Trends Cancer
2015; 1(4): 217–230.
8. Euhus DM, Timmons CF, Tomlinson GE. ETV6-NTRK3–Trk-ing the
primary event in human secretory breast cancer. Cancer Cell 2002; 2(5):
347–348.
9. Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer: pCA3
and TMPRSS2: eRG gene fusion. J Urol 2012; 187(3): 795–801.
10. Stephens PJ, Greenman CD, Fu B et al. Massive genomic rearrangement
acquired in a single catastrophic event during cancer development. Cell
2011; 144(1): 27–40.
11. Baca SC, Prandi D, Lawrence MS et al. Punctuated evolution of prostate
cancer genomes. Cell 2013; 153(3): 666–677.
12. Ferrari A et al. A whole-genome sequence and transcriptome perspective
on HER2-positive breast cancers. Nat Commun 2016; 7: 12222.
13. Nilsson B, Johansson M, Heyden A et al. An improved method for
detecting and delineating genomic regions with altered gene expression
in cancer. Genome Biol 2008; 9(1): R13.
14. Bautista S, Theillet C. CCND1 and FGFR1 coamplification results in the
colocalization of 11q13 and 8p12 sequences in breast tumor nuclei.
Genes Chromosomes Cancer 1998; 22(4): 268–277.
15. Paterson AL, Pole JCM, Blood KA et al. Co-amplification of 8p12 and
11q13 in breast cancers is not the result of a single genomic event. Genes
Chromosom Cancer 2007; 46(5): 427–439.
16. PCAWG-Structural Variation Working Group, t.P.N., Selective and
mechanistic sources of recurrent rearrangements across the cancer gen-
ome. bioRxiv 2018; https://doi.org/10.1101/187609(187609) (6
November 2018, date last accessed).
Annals of Oncology Original article
Volume 29 | Issue 11 | 2018 doi:10.1093/annonc/mdy404 | 2231
